Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Miraca Holdings Inc.    4544   JP3822000000

MIRACA HOLDINGS INC.

(4544)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Miraca unit seeks approval for Japan's first coronavirus antigen tests

share with twitter share with LinkedIn share with facebook
04/27/2020 | 11:40am EDT

Fujirebio, a subsidiary of Japanese diagnostics and laboratory testing service provider Miraca Holdings, applied on Monday for government approval for Japan's first antigen coronavirus testing kits, a health ministry official said.

Japan's sole official test for coronavirus diagnosis is a polymerase chain reaction, or PCR, test. Antigen tests can be conducted more quickly, in about half an hour, potentially making virus tests more accessible to the public if approved.

The application will be fast-tracked, the official said.

"We usually aim to complete our review for approval within a year. But we will tackle this one as swiftly as possible," Takuma Kato, deputy director of the ministry's tuberculosis and infectious diseases control division, told Reuters.

Approval will likely be issued by the end of May, Kyodo news agency said, without citing sources.

There has been widespread criticism that phone lines for public health centres, tasked with conducting screening for PCR test candidates, are always busy and test results are slow to come by.

Critics say the low rate of testing in Japan has made it difficult to trace the new coronavirus, which can cause the COVID-19 respiratory disease, as it spreads and that this has led to a series of in-hospital infections, crippling some facilities.

Japan conducted about 52,000 PCR tests in March, or just 16% of the number carried out in South Korea, according to data from Oxford University.

A Miraca Holdings spokeswoman confirmed Fujirebio had filed for government approval but declined to give details, saying an official announcement would be made soon.

An antigen test targets the virus's protein to establish whether a person has the disease. An antibody test is used to detect those who have been infected with the virus and therefore had immunity.

Japan had reported 13,613 coronavirus infections as of late Monday evening, with 394 deaths, public broadcaster NHK said.

By Kiyoshi Takenaka

Stocks mentioned in the article
ChangeLast1st jan.
LETS HOLDINGS GROUP CO., LTD. 3.09% 12 End-of-day quote.98.68%
LOOK HOLDINGS INCORPORATED 5.99% 726 End-of-day quote.-42.01%
MIRACA HOLDINGS INC. 1.88% 2550 End-of-day quote.-4.96%
share with twitter share with LinkedIn share with facebook
Latest news on MIRACA HOLDINGS INC.
06/05Hitachi, Toshiba, Miraca to set up factory for coronavirus antigen tests
RE
04/27Miraca unit seeks approval for Japan's first coronavirus antigen tests
RE
03/30MIRACA HOLDINGS INC. : Ex-dividend day for final dividend
FA
2019MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
2019MIRACA HOLDINGS INC. : Ex-dividend day for final dividend
FA
2018MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
2018MIRACA HOLDINGS INC. : Ex-dividend day for final dividend
FA
2017MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
2017MIRACA HOLDINGS INC. : Ex-dividend day for final dividend
FA
2016MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
More news
Financials
Sales 2021 194 B 1 813 M 1 813 M
Net income 2021 3 724 M 34,7 M 34,7 M
Net Debt 2021 48 190 M 450 M 450 M
P/E ratio 2021 39,0x
Yield 2021 4,39%
Capitalization 145 B 1 355 M 1 356 M
EV / Sales 2020
EV / Sales 2021 1,00x
Nbr of Employees 5 968
Free-Float 99,1%
Chart MIRACA HOLDINGS INC.
Duration : Period :
Miraca Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRACA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 2 490,00 JPY
Last Close Price 2 550,00 JPY
Spread / Highest target 6,27%
Spread / Average Target -2,35%
Spread / Lowest Target -7,84%
EPS Revisions
Managers
NameTitle
Shigekazu Takeuchi President & Director
Naoki Kitamura Chief Financial Officer & Director
Hiroaki Kimura Head-Information Technology & Investor Relations
Kazuya Omi Executive Officer, Head-Research & Development
Ryoji Itoh Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
MIRACA HOLDINGS INC.-4.96%1 336
EXACT SCIENCES CORPORATION-0.43%13 789
GUARDANT HEALTH, INC.9.05%8 427
ADAPTIVE BIOTECHNOLOGIES CORPORATION53.51%5 828
IOVANCE BIOTHERAPEUTICS, INC.6.61%4 318
INVITAE CORPORATION107.50%4 184